1. Introduction
===============

Ovarian cancer (OC) is 1 of the most lethal gynecologic cancers, and also the leading cause of cancer-related deaths.^\[[@R1]--[@R2]\]^ Despite the research of CC achieved greatly during the past few decades, almost 70% of the patients relapse, and developed to advanced ovarian cancer (AOC).^\[[@R3]--[@R7]\]^ Thus, effective therapy schedule is very important to treat patients with AOC, such as weekly paclitaxel (WP).^\[[@R8]--[@R12]\]^ Although many studies have assessed the efficacy and safety of WP for the treatment of patients with AOC,^\[[@R11]--[@R25]\]^ no systematic review has been done on this topic. Therefore, this study will include only gather data from eligible randomized controlled trials (RCTs) to provide further knowledge on the efficacy and safety of WP for the treatment of AOC.

2. Methods
==========

2.1. Study registration
-----------------------

This protocol has been registered on INPLASY202040193. We report it based on the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocol statement.^\[[@R26]--[@R27]\]^

2.2. Ethics and dissemination
-----------------------------

This study will not need ethical approval, since no personal patient data will be used. This study is expected to be published on a peer-reviewed journal.

2.3. Eligibility criteria for study selection
---------------------------------------------

### 2.3.1. Type of studies

This study will include RCTs that assessed the efficacy and safety of WP for the treatment of AOC. We will exclude other studies, such as animal studies, reviews, comments, case studies, non-controlled trials, and non-RCTs.

### 2.3.2. Type of participants

This study will include any patients who were diagnosed as AOC, irrespective nationality, race, sex, and economic status.

### 2.3.3. Type of interventions

In the interventional group, all patients who received WP will be included as their therapy.

In the control group, all patients who could receive any treatments will be included as their comparator.

### 2.3.4. Type of outcome measurements

Outcomes are overall survival, pathological complete response, cancer-specific survival, recurrence-free survival, disease-free survival, and adverse events.

2.4. Data sources and search strategy
-------------------------------------

Two authors will perform systematic and comprehensive literature sources in bibliographic databases (MEDLINE, EMBASE, Cochrane Library, Web of Science, CINAHL, PSYCINFO, Allied and Complementary Medicine Database, CNKI, WANGFANG, and Chinese Biomedical Literature Database) from inception to the March 1, 2020 without language and publication time restrictions. We present search strategy of MEDLINE in Table [1](#T1){ref-type="table"}, and will adapt similar search strategies for other electronic databases. In addition, we will identify other literature sources from dissertations, thesis, conference abstracts, and reference lists of relevant reviews.
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2.5. Data collection and management
-----------------------------------

### 2.5.1. Study selection

Two authors will independently screen the titles/abstracts of all searched literatures, and all unconnected studies will be eliminated. The full papers of all potential studies will be obtained to further identify them against inclusion criteria. If any disagreements between 2 authors occur, a third author will solve them through discussion, and a final decision will be reached. We will present results of study selection in a flowchart.

### 2.5.2. Data extraction

Two authors will conduct data extraction using a standardized data collection. Any conflicts between 2 authors will be resolved by a third author via discussion. The extracted information includes publication information (eg, title, first author, year of publication), participant information (eg, gender, age, and eligibility criteria), study methods, details of treatments and controls (eg, types of interventions, dosage, and frequency), outcome indicators, results, and conclusions.

If we identify any unclear or missing data, we will contact primary authors to request those data. If we can not obtain such data, we will utilize and analyze available data only.

2.6. Risk of bias assessment
----------------------------

Two authors will use Cochrane risk of bias tool to assess risk of bias for each included trial, respectively. It includes 7 items and each 1 is rated as high, unclear, and low risk of bias. Any discrepancies will be solved through discussion with the help of a third author.

2.7. Treatment effect measurements
----------------------------------

We will express continuous outcomes as mean differences or standardized mean differences and 95% confidence intervals (CIs), and dichotomous outcomes as risk ratios or odds ratios and 95% CIs.

2.8. Statistical analysis
-------------------------

This study will utilize RevMan V.5.3 software to synthesize and analyze the data. *I*^*2*^ statistic test will be used to check heterogeneity across included trials. *I*^*2*^ ≤50% means acceptable heterogeneity, and we will use a fixed-effect model to pool the data, and to conduct a meta-analysis. On the other hand, *I*^*2*^ \>50% indicates obvious heterogeneity, and we will use a random-effect model to synthesize data. In addition, we will undertake subgroup analysis and sensitivity analysis to explore the sources of remarkable heterogeneity. If necessary, a narrative summary will be conducted to report merged outcome results.

Subgroup analysis will be carried out according to the different study information, treatments, controls and outcomes. Sensitivity analysis will be performed to test the robustness of study findings by eliminating low quality trials. Reporting bias will be examined by funnel plots and Egger linear regression test if over 10 trials are included.^\[[@R28]--[@R29]\]^

3. Discussion
=============

Recent clinical studies have indicated that WP might benefit for patients with AOC.^\[[@R11]--[@R25]\]^ Up to now, there is no published systematic review on WP for the treatment of AOC. This study will synthesize relevant data comprehensively and systematically to reflect the integrated efficacy and safety of the eligible trials. The results of this study may provide high-quality evidence-based medicine evidence to determine whether WP is effective and safe for the treatment of patients with AOC or not.
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